In September 2012, the New England Journal of Medicine reported that dimethyl fumarate (BG12) significantly reduced the annual relapse rate in patients with relapsing-remitting multiple sclerosis and significantly reduced the number of new intracranial lesions relative to the placebo group. The two main disease-modifying therapeutic agents currently available in China for multiple sclerosis are interferons: Libri and Betaseron. The advantage of dimethyl fumarate (BG12), a new drug for disease modifying therapy, is that it is an oral formulation that does not require injections and is no less effective than interferon. The drug has already applied for registration and marketing in Europe and America. It is believed that it will become a brand new treatment option for Chinese patients in the future.